SUMMER SCHOOL HEALTH AND WEALTH - CONVERGING PATHWAYS IN ALZHEIMER AND PARKINSON DISEASE

The Summer School “Biological and Clinical converging pathways in Alzheimer and Parkinson disease” is an opportunity for young neurologists who are interested in specializing in Neurodegenerative diseases to receive in-depth instruction from internationally-recognized experts. Students will attend large lectures and panel discussions with question and answer sessions and will have the opportunity to discuss clinical cases of atypical dementia and movement disorders and engage in a differential diagnosis with the international experts.

Educational need: 

The management strategies  of patients affected by neurodegenerative disease need a deep expertise in clinical and imaging assessment. New biological markers and imaging techniques enable the assessment of neurotransmission pathways and neurodegenerative alterations in the brain and could thus be used as target of newly developed disease-modifying therapies. 

Course Description: 

The Summer School “Converging pathways in Alzheimer and Parkinson disease: management strategies and disease modifying treatments” is an opportunity for young neurologists and neuroscientists who are interested in specializing in Neurodegenerative diseases to receive in-depth instruction from internationally-recognized experts. Students will attend large lectures and panel discussions with question and answer sessions and will have the opportunity to discuss clinical cases of atypical dementia and movement disorders and engage in single case treatment and management with the international experts.

The purpose of the summer school is to provide a in depth-education course to international audience interested in neurodegenerative diseases. The specific learning Objectives are

•Propose a personalized pharmacological treatment in patients presenting with dementia or movement disorders 

•Propose new on-pharmacological management strategies for dementia and movement disorder

•Understand the rationale and review the more recent evidences for new disease-modifying target therapies across neurodegenerative diseases

Audience target:

Undergraduate and Graduate medical Doctor (Neurologist, Geriatrician, Psychiatrist) Neuropshychologist

Biologist

Neuroscientist

Biotechnologist

Pharmacologist